证券代码：000597 证券简称：东北制药 公告编号：2025-047 东北制药集团股份有限公司关于控股股东一致行动人 增持计划实施完成的公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 方大集团实业有限公司（简称"方大集团"）一致行动人江西方大钢铁集团有限 公司（以下简称"方大钢铁/增持主体"）计划自 2024 年 12 月 11 日起 6 个月内 增持公司股份，计划增持金额不少于人民币 7,500 万元,不超过人民币 15,000 万 元。 圳证券交易所以集中竞价交易方式合计增持公司股份 14,629,900 股，占公司总 股本比例的 1.0237%，合计增持金额为 7,500.4222 万元（不含交易费用），本次 增持计划已实施完成。 （二）增持计划披露前，增持主体已持有公司股份数量及比例：公司控股股 东为方大集团，直接持有公司 329,068,713 股股份，占公司总股本的 23.03%，方 大钢铁直接持有公司 443,231,442 股 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The controlling shareholder, Juzi Holding, plans to increase its stake in the company by at least HKD 200 million within 3-6 months, reflecting strong confidence in the company's future [2][3]. - The company aims to enhance its brand, expand distribution channels, and strengthen regulatory approvals, focusing on product development and marketing efforts [4]. - The projected earnings per share (EPS) for 2025-2027 are estimated at CNY 2.40, CNY 2.93, and CNY 3.54, with corresponding price-to-earnings (PE) ratios of 23, 19, and 16 [5][11]. Summary by Sections Event Commentary - Juzi Holding announced a plan to increase its shareholding, indicating confidence in the company's prospects [2]. Operational Analysis - Juzi Holding currently holds approximately 54.26% of the company's shares and plans to acquire an additional 3.268 million shares, representing about 0.3% of the total share capital [3]. - The company will focus on increasing R&D investment and enhancing its product offerings, particularly in three categories of medical devices [4]. Future Outlook - The company plans to strengthen its marketing for key brands and develop new brands to support growth in its skincare business [4]. - The product matrix, including medical devices and skincare lines, is expected to continue driving growth [5]. Financial Forecasts - Revenue is projected to grow from CNY 3,524 million in 2023 to CNY 10,921 million by 2027, with a compound annual growth rate (CAGR) of approximately 23.95% [11]. - Net profit is expected to increase from CNY 1,452 million in 2023 to CNY 3,790 million by 2027, reflecting a strong growth trajectory [11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688222 证券简称：成都先导 公告编号：2025-018 重要内容提示： ● 本次增持主体宁波聚智先导生物科技合伙企业（有限合伙）（以下简称"聚智先导"）为成都先导药物 开发股份有限公司（以下简称"公司"或"成都先导"）持股5%以上股东、员工持股平台，与公司控股股 东、实际控制人JIN LI（李进）为一致行动人关系。截至本公告披露日，聚智先导持有公司38,651,163 股股份，占总股本的比例为9.65%，JIN LI（李进）持有公司81,876,948股股份，占总股本的比例为 20.43%，聚智先导与JIN LI（李进）合计持有公司120,528,111股股份，占总股本的比例为30.08%。 ● 成都先导于今日收到公司控股股东、实际控制人JIN LI（李进）的一致行动人聚智先导的通知，基于 对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，聚智先导拟自本公告披露之日起 12个月内，通过包括但不限于集中竞价、大宗交易等上海证券交易所交易系统允许的方式增持公司股 份，合计增持金额不低于人民币2,500万元（含）且不高于人民币5,000万 ...

Group 1 - Daqian Ecology announced that shareholder Xinhua Publishing Group plans to reduce its stake by up to 4,071,600 shares, representing no more than 3% of the total share capital [2] - Vice President Wang Zheng'an intends to reduce his holdings by up to 410,798 shares, which is no more than 25% of his total holdings and approximately 0.3027% of the company's total share capital [2] - The reduction period is set from June 16, 2025, to September 15, 2025 [2] Group 2 - Sanofi's stock has experienced a significant increase, with a cumulative rise of over 30% in two consecutive trading days and over 100% in four consecutive trading days, indicating abnormal trading fluctuations [2] - The company has entered into a collaboration with Pfizer for the 707 project, which involves a dual-specific antibody product targeting PD-1 and VEGF, with uncertain sales milestone payments and royalties based on market conditions [2] - The actual receipt of sales milestone payments and royalties is subject to uncertainties related to drug demand, market competition, and sales channels [2] Group 3 - Xinhua Insurance announced a commitment to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total fund size of 20 billion yuan [3] - The establishment of the fund is pending regulatory procedures, and the implementation timeline may vary [3] - Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, with the application materials being subject to updates [3] Group 4 - Laisentongling's stock has seen a 33.17% increase over three consecutive trading days, with a turnover rate of 40.49%, indicating potential speculative trading [3] - The company confirmed that its main operations remain stable, with no significant changes in daily operations or major contracts signed recently [3] - The production costs and sales conditions are reported to be normal [3]

Core Viewpoint - China Petroleum & Chemical Corporation (Sinopec) announced a share buyback plan, indicating confidence in the company's future performance and potential for value creation [1] Group 1: Share Buyback Details - On May 14, 2025, Sinopec Group, through its wholly-owned subsidiary, increased its stake in the company by acquiring 302 million H-shares, representing approximately 0.25% of the total issued shares [1] - The total amount spent on this acquisition was HKD 1.232 billion [1] - Following this transaction, Sinopec Group now holds a total of 1.345 billion H-shares in the company [1] Group 2: Future Plans - Sinopec Group and its concerted parties plan to continue increasing their shareholding in the company according to their buyback strategy [1]

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 厦门国贸集团股份有限公司（以下简称"公司"）控股股东厦门国贸控股集团有限公司（以下简称"国 贸控股"）于2024年10月31日至2025年4月30日期间，通过上海证券交易所（以下简称"上交所"）集中竞 价交易等方式增持公司股份43,238,100股，占公司已发行股份的1.995%，累计增持金额27,807.77万元。 本次增持计划已实施完毕。 ● 本次增持计划完成后，国贸控股及其一致行动人合计持有公司股份840,076,581股，占公司已发行股份 的38.759%。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600755 股票简称：厦门国贸 编号：2025-35 厦门国贸集团股份有限公司 关于控股股东以专项贷款和自有资金 增持公司股份计划实施完毕暨增持届满的公告 4．公司于2025年4月17日在上交所网站（http://www.sse.com.cn）披露了《关于控股股东以专项贷款和 自有资金增持公司股份计划的进展公告》（公告编号：2 ...

人福医药(600079.SH)公告称，招商生物拟自本公告披露之日起6个月内，通过证券交易所集中竞价交 易、大宗交易等方式增持公司股份，累计增持比例不低于增持前公司已发行总股本的0.5%，不高于 1%，增持价格上限为25.53元/股。增持主体招商生科目前未持有公司股份，其通过当代科技重整计划控 制公司23.70%表决权。增持目的基于对公司未来发展的信心和 长期投资价值的认可。增持计划可能面 临资本市场变化等风险。 ...

4月以来，宁德时代、美的集团、五粮液、立讯精密、京东方A、潍柴动力等一批深市龙头企业先后抛 出回购增持方案，展现对公司未来发展的信心和对公司价值的认可。 具体来看，4月7日，宁德时代继2024年10月30日完成前次27.1亿元的回购计划之后，再次推出回购公司 股份方案，基于对公司未来发展的信心和对公司价值的认可，为增强投资者对公司的投资信心，同时为 进一步健全公司长效激励机制，充分调动员工的积极性，有效地将股东利益、公司利益和员工个人利益 紧密结合在一起，公司拟以40亿至80亿元回购公司股份，用于实施股权激励计划或员工持股计划。 股份回购在优化公司资本结构、维护公司投资价值、健全投资者回购机制等方面发挥着重要作用，股份 增持彰显股东对公司投资价值的认可。一直以来，深市公司、股东积极开展回购增持，持续向市场传达 积极信号，提升股东回报水平。 4月以来深市掀起了新一轮的回购增持热潮。数据显示，其间，深市600家公司披露回购增持公告，其 中，回购计划106家，拟回购金额202亿至366亿元；回购进展426家；增持计划27家，拟增持金额为67亿 至97亿元；增持进展41家。 头部公司领衔 4月8日，美的集团继2025 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002972 证券简称：科安达 公告编号：2025-019 深圳科安达电子科技股份有限公司 关于公司监事增持公司股份的公告 公司监事肖泽玲女士保证向本公司提供的信息内容真实、准确、完整、没有虚假记载、误导性陈述或重 大遗漏。 本公司及董事会全体成员保证公告的内容与信息披露义务人提供的信息一致。 深圳科安达电子科技股份有限公司（以下简称"公司"）于2025年4月11日收到公司监事肖泽玲女士出具 的《股份增持情况告知函》，肖泽玲女士通过深圳证券交易所以集中竞价交易方式增持部分公司股份， 现将有关情况公告如下： 一、本次增持情况说明 1.增持主体：肖泽玲 3.增持方式：集中竞价交易 4.资金来源：自有资金 5.增持时间：2025年4月10日 6.增持股份情况： ■ 7.截至本公告披露日，肖泽玲女士暂未提出后续增持计划。 二、其他事项说明 1、肖泽玲女士本次股份增持符合《证券法》《深圳证券交易所上市公司自律监管指引第10号一一股份 变动管理》等法律、法规、部门规章及深圳证券交易所业务规则等有关规定。 2、肖泽玲女士本次股份增持不会导致公司股权分布不具备上市条 ...

Core Viewpoint - Qingdao Haier Biomedical Co., Ltd. announced that its actual controller's concerted action party, Haichuangzhi, has completed a share buyback plan, acquiring 5,729,305 shares, which is 1.8% of the total share capital, for a total amount of 181.84 million yuan [2][8]. Group 1 - The share buyback plan was initiated on January 8, 2025, with a target to purchase between 100 million yuan and 200 million yuan within six months [2][6]. - As of April 10, 2025, Haichuangzhi has completed the buyback, with an average purchase price of 31.74 yuan per share [7][8]. - Following the buyback, Haichuangzhi holds 8,675,900 shares, representing 2.73% of the total share capital, while Haier Group and its concerted action parties collectively hold 141,371,022 shares, or 44.46% of the total [8]. Group 2 - The purpose of the buyback is to enhance investor confidence based on the belief in the company's future development and long-term investment value [4]. - The buyback was executed through a centralized bidding method on the Shanghai Stock Exchange [7]. - The buyback plan did not set a price range and was subject to market conditions [7].